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Abstract Glioblastoma (GBM) is the most aggressive
form of primary brain tumour, with dismal patient out-
come. Treatment failure is associated with intrinsic or
acquired apoptosis resistance and the presence of a highly
tumourigenic subpopulation of cancer cells called GBM
stem cells. Tumour necrosis factor-related apoptosis-
inducing ligand (TRAIL) has emerged as a promising
novel therapy for some treatment-resistant tumours but
unfortunately GBM can be completely resistant to TRAIL
monotherapy. In this study, we identified Mcl-1, an anti-
apoptotic Bcl-2 family member, as a critical player
involved in determining the sensitivity of GBM to TRAIL-
induced apoptosis. Effective targeting of Mcl-1 in TRAIL
resistant GBM cells, either by gene silencing technology or
by treatment with R-roscovitine, a cyclin-dependent kinase
inhibitor that targets Mcl-1, was demonstrated to augment
sensitivity to TRAIL, both within GBM cells grown as
monolayers and in a 3D tumour model. Finally, we high-
light that two separate pathways are activated during the
apoptotic death of GBM cells treated with a combination of
TRAIL and R-roscovitine, one which leads to caspase-8
and caspase-3 activation and a second pathway, involving a
Mcl-1:Noxa axis. In conclusion, our study demonstrates
that R-roscovitine in combination with TRAIL presents a
promising novel strategy to trigger cell death pathways in
glioblastoma.
Keywords Glioblastoma  TRAIL  R-roscovitine 
Mcl-1
Abbreviations
Bcl B cell lymphoma
Bid BH3 interacting-domain death agonist
BH Bcl-2 homology
GBM glioblastoma
GSC GBM stem cells
Mcl-1 myeloid cell leukaemia-1
Rosc R-roscovitine
tBid truncated BID
TRAIL tumour necrosis factor-related apoptosis-
inducing ligand
Introduction
Glioblastoma (GBM) is the most common and aggressive
primary brain tumour that occurs in humans. The current
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standard of care for GBM patients is surgical resection
followed by chemotherapeutic treatment with the alkylat-
ing cytostatic drug temozolomide, in combination with
radiotherapy [1]. Despite this treatment strategy, the aver-
age period of survival of GBM patients is approximately
12 months [2].
GBM cells display extreme resistance to apoptotic
stimuli which contributes to the limited effectiveness of
current therapies and the difficulty in developing new
efficacious treatment regimes. Contributing to this phe-
nomenon in GBM is the overexpression of numerous sur-
vival proteins and attenuated levels of several pro-
apoptotic proteins [3–5] which results in resistance to the
execution of both intrinsic and extrinsic apoptotic path-
ways. Apoptotic resistance in GBM is compounded by the
presence of a highly tumourigenic subpopulation of cancer
cells called GBM stem cells (GSCs) [6, 7] that are extre-
mely chemoresistant and radioresistant and drive the
growth and progression of the tumour, especially after
treatment [8–12]. Therefore, the resistance to apoptotic
stimuli of both the differentiated tumour cells and the
GSCs must be actively targeted by GBM therapy to ensure
complete eradication of the tumour [8, 11].
A promising novel therapy for treatment-resistant
tumours has emerged in recent years in the form of the
extracellular ligand, tumour necrosis factor-related apop-
tosis-inducing ligand (TRAIL). TRAIL induces apoptosis
when it binds the death receptors DR4/TRAIL-R1 and
DR5/TRAIL-R2, leading to DISC formation and the pro-
cessing and activation of procaspase-8 [13–15]. The
apoptotic signal from the DISC may be inhibited by cel-
lular FLICE-inhibitory protein (FLIP) [16]. However, once
procaspase-8 has been activated, TRAIL-induced apoptotic
signalling may be propagated either by a mitochondrial-
independent or a mitochondrial-dependent pathway [14].
TRAIL was originally identified as an attractive candidate
for clinical use as it selectively induces apoptosis in cancer
cells while sparing normal tissue [14, 17]. Indeed such
cancer-selective properties of TRAIL have been identified
for glioma cells in comparison to non-neoplastic astrocytes
in vitro [18]. Unfortunately, numerous studies have dem-
onstrated that many malignancies, including GBM, are
completely resistant to monotherapy with TRAIL [17, 19].
This resistance may be due to the overexpression of anti-
apoptotic Bcl-2-like proteins, such as Bcl-2 and Bcl-xL
[20–22]. Many reports have also suggested that sensitivity
to TRAIL-induced apoptosis is dependent on the expres-
sion levels of another anti-apoptotic Bcl-2 family member,
myeloid cell leukemia-1 (Mcl-1) [23–25]. Mcl-1 is pri-
marily localized at the mitochondrial membrane [26] where
it can block the release of cytochrome c [27] thus inhibiting
apoptosis. Like other anti-apoptotic Bcl-2 family members,
Mcl-1 interacts with high affinity to the pro-apoptotic BH3-
only proteins Bim, Bid and Puma; but it also selectively
interacts with Noxa and Bak, blocking their pro-apoptotic
function [28–30]. The contribution of Mcl-1 to TRAIL
resistance in GBM is currently unknown.
In this study, we examine the role of Mcl-1 in the
resistance of GBM to TRAIL and identify R-roscovitine as
a potential candidate drug that targets Mcl-1 to enhance the
therapeutic effects of TRAIL in the treatment of TRAIL
resistant GBM cells and in a 3D tumour model.
Materials and methods
Cell culture of GBM cell lines and neurospheres
For this study, glioblastoma cell lines A172 and U87 and a
glioblastoma cell line derived from a primary tumour, MZ-
294 [22], were grown as a monolayer in DMEM with 10 %
heat-inactivated fetal calf serum, 100 U/ml penicillin, and
100 mg/ml streptomycin and maintained in a humidified
incubator at 37 C and 5 % CO2. To generate MZ-294
neurospheres, the MZ-294 monolayer cells were washed in
PBS (59) and 1 9 106 cells were seeded in a T25 flask
(Greiner) or 2 9 105 cells seeded in a six well-plate in
DMEM-F12 medium (Gibco) containing 5 % sodium
bicarbonate buffer solution (Life technologies), B27 sup-
plement (Life technologies), penicillin (100 U/ml, Sigma),
streptomycin (100 mg/ml, Sigma), Hepes buffer (1 M;
Gibco), ITS liquid media supplement (Sigma), D-glucose
solution (45 %; Sigma), progesterone (20 lM, Sigma),
putrescine (100 lM, Sigma), heparin (2 %, Sigma), epi-
dermal growth factor (0.1 lg/ml; Peprotech) and fibroblast
growth factor (0.01 lg/ml; Peprotech) and maintained in a
humidified incubator at 37 C and 5 % CO2. The neuro-
spheres were visualised using an Eclipse TE 300 inverted
microscope (Nikon, Du¨sseldorf, Germany).
MTT cell viability assay
MZ-294, U87 and A172 cells were plated in 96-well plates
(2,000 cells/well) and treated with R-roscovitine (20 lM;
Cayman Chemical) or TRAIL (100 ng/ml; Enzo Life Sci-
ence) for 24, 48 and 72 h. In addition, MZ-294 were plated
in 96-well plates (2,000 cells/well) and treated with
R-roscovitine (20 lM), TRAIL (100 ng/ml), R-roscovitine
(20 lM) ? TRAIL (100 ng/ml) for 48 h. Following treat-
ment, thiazolyl blue tetrazolium bromide (MTT, 5 mg/ml;
Sigma) was added to each well and incubated in the dark at
37 C. MTT produces a yellowish solution that is con-
verted to dark blue, water-insoluble MTT formazan by
mitochondrial dehydrogenases of living cells. After 4 h,
the medium was aspirated and the dark blue crystals were
dissolved in DMSO (200 ll). The absorbance of each
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sample was measured at 560 nm using a microplate reader
(GENios, Tecan). The absorbance was proportional to the
number of viable cells and expressed relative to control
treated cultures.
Transfection of GBM cell lines
A172, U87 and MZ-294 cells were transfected with human
Mcl-1 knockdown 29mer shRNA construct in a retroviral
GFP vector (Origene) and MZ-294 cells were transfected
with human Noxa knockdown 29mer shRNA construct in a
retroviral GFP vector (Origene) using calcium phosphate
transfection kit (Life Technologies) as per manufacturer’s
instructions.
Hoechst staining of nuclear chromatin
Cells were treated as indicated and stained with Hoechst
33258 (1 lg/ml; Sigma), incubated for 10 min at 37 C
and nuclear morphology was visualised using an Eclipse
TE 300 inverted microscope (Nikon, Du¨sseldorf, Germany)
using a 20 9 dry objective. A minimum of 300 cells were
counted in three subfields of each culture. Those cells with
condensed/fragmented nuclei were deemed apoptotic,
counted using Image J software and expressed as a per-
centage of total cell number. In the case of transfected
cells, only GFP? cells were counted and apoptotic cells
were expressed as a percentage of GFP? cells.
Western blot analysis
Western blot analysis was performed on lysates prepared
from MZ-294, A172 and U87 cells treated as indicated.
Cells were homogenised in lysis buffer containing
0.5 mmol/l Tris-Cl (pH 6.8), 2 % SDS (w/v), 10 % glyc-
erin (w/v) and protease and phosphatase inhibitor cocktails
(Sigma-Aldrich, Dublin). After determining the protein
concentration of the samples using a BCA protein assay
(Pierce, Illinois, USA), 20 lg samples were boiled in gel-
loading buffer and separated on 10–15 % SDS-PAGE gels.
Proteins were transferred to nitrocellulose membranes
using the iBlot gel transfer device (Life Technologies,
Ireland). The membranes were incubated with anti-human
Mcl-1 (BD Biosciences, Oxford, UK), anti-human pro-
caspase-8 and cleaved caspase-8, anti-human Bid and tBid,
anti-human procaspase-3 and cleaved caspase-3 antibodies
(Cell signalling Technology, Beverly, MA, USA) and anti-
human Noxa, anti-human DR4 and anti-human DR5 (Ab-
cam, Cambridge, UK) overnight at 4 C. Membranes were
next incubated with horseradish peroxidase-conjugated
secondary antibodies (Jackson ImmunoResearch, Plym-
outh, PA, USA) and protein bands were visualised using
Supersignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL, USA). Images were captured using
Fuji-film LAS-3000 (Fuji, Sheffield, UK).
Flow cytometry
MZ-294, A172 and U87 cells were plated in 24-well plates
(15,000 cells/well) and treated with R-roscovitine (20 lM)
for 24, 48 and 72 h. MZ-294 neurospheres and MZ-294
monolayer cells were treated with R-roscovitine (20 lM),
TRAIL (100 ng/ml) and R-roscovitine (20 lM) ? TRAIL
(100 ng/ml) for 48 h. Following treatment, monolayer cells
were harvested with trypsin–EDTA and washed with PBS.
In the case of neurospheres, spheres were pelleted, disso-
ciated in accutase (Life Technologies) for 10 min at 37 C
and washed in PBS. Cells were then incubated at room
temperature in binding buffer (10 mM HEPES, 135 mM
NaCl, 5 mM CaCl2) which contained an Annexin V-FITC
conjugate (1 ll/ml; BioVision, Mountain View, CA, USA)
and propidium iodide (PI; 1 ll/ml, BioVision) for 15 min.
Cells were counted in a Cyflow ML 16 flow cytometer
(Partec, Mu¨nster, Germany). Excitation of Annexin
V-FITC was done with a 488 nm laser and fluorescence
emission was collected in the FL1 channel through a
520 nm band pass filter. PI was excited with a 488 nm laser
and fluorescence emission was collected in the FL3 chan-
nel through a 620 nm long pass filter. 1 9 104 gated cells
were acquired for each sample and analyzed using the
Flowmax software (Partec).
Measurement of Noxa-induced MOMP in MZ-294
and A172 cells
Measurement of mitochondrial depolarisation, as indicated
by ratiometric fluorescent dye JC1, was assessed in A172
and MZ-294 cells treated with Noxa BH3 peptide as pre-
viously described [31]. Noxa BH3 peptide (synthesised by
Tufts University Core Facility), a negative control (DMSO)
and a positive control carbonyl cyanide 4-(trifluorometh-
oxy)-phenylhydrazone (FCCP) were deposited into each
well in triplicate in T-EB (15 ll; 300 mM Trehalose,
10 mM Hepes-KOH pH 7.7, 80 mM KCl, 1 mM EGTA,
0.1 % BSA, 5 mM succinate) in a black 384-well plate
(BD Falcon). Single cell suspensions of MZ-294 and A172
cells were washed in T-EB before being resuspended at
4 9 their final density (1 9 104 cells/well). One volume of
the 4 9 cell suspension was added to one volume of a
4 9 dye solution containing 4 lM JC-1 (Life technolo-
gies), 40 lg/ml oligomycin, 0.02 % digitonin, 20 mM
2-mercaptoethanol in T-EB. This 2 9 cell/dye solution
was incubated for 5–10 min at RT to allow permeabiliza-
tion and dye equilibration. A total of 15 ll of the 2 9 cell/
dye mix was then added to each treatment well to give a
final Noxa BH3 peptide concentration of 100 lM. The
Apoptosis (2014) 19:629–642 631
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plate was shaken for 15 s inside the plate reader (Tecan
Safire 2), and the fluorescence at 590 nm was recorded
every 5 min at RT for 3 h. The area under the curve of JC-
1 fluorescence intensity (545 nm excitation and 590 nm
emission) was calculated, and the depolarization reported
in response to Noxa BH3 peptide is normalized relative to
the area under the curve in the presence of a negative
control, DMSO (0 %), and a positive control, the mito-
chondrial uncoupling agent FCCP (100 %).
Immunostaining
For immunocytochemical staining, MZ-294 monolayer
cells were grown on 13 mM coverslips (Fisher Scientific
Ireland) in 24 well plates (15,000 cells/well). MZ-294
neurospheres were dissociated in accutase at 37 C for
10 min and the single cell suspension (3 9 105 cells/ml)
was cytospun onto glass slides (VWR International) using a
Shandon CytoSpin III Cytocentrifuge as per manufac-
turer’s instructions. Cells on the coverslips and slides were
fixed in ice cold methanol for 10 min, blocked in 5 % goat
serum, washed in PBS containing 0.2 % Tween (49) and
incubated overnight with rabbit anti-human CD133 anti-
body (Cell signalling Technology, Beverly, MA, USA) at
4 C. Cells were washed in PBS containing 0.2 % Tween
(49) and incubated with PE-conjugated secondary anti-
bodies (Life technologies, Molecular Probes). Cells were
then incubated overnight with mouse anti-human nestin
antibody (R and D Systems) at 4 C, washed in PBS
containing 0.2 % Tween (49) and incubated with FITC-
conjugated secondary antibodies (Life technologies,
Molecular Probes). Lastly, coverslips were mounted on
glass slides and glass slides were covered with rectangular
coverslips using DAPI-containing VectaShield (Vector
Laboratories, CA). Staining was visualised using an
Eclipse TE 300 inverted microscope (Nikon, Du¨sseldorf,
Germany) using a 209 dry objective.
Gene expression analysis using quantitative real-time
RT-PCR
Total RNA was extracted using the RNeasy Mini Kit
(Qiagen, UK). First-strand cDNA synthesis was performed
with 1 lg total RNA as template and Superscript II reverse
transcriptase (Life technologies, UK) primed with 50 pmol
random hexamers (Thermo Scientific, USA). Quantitative
real-time PCR was performed using a LightCycler 1.5
(Roche Diagnostics, UK) in combination with QuantiTect
SYBR Green PCR kit (Qiagen) as per manufacturer’s
protocol. The data were analysed using LightCycler Soft-
ware 4.0, normalized to expression of b-actin and repre-
sented as relative quantification values. Specific primers
were designed using Primer3 software (http://frodo.wi.mit.
edu/primer3/). Sense and antisense primer sequences were
as follows Mcl-1 Forward: TGC TGG AGT AGG AGC
TGG TT, Mcl-1 Reverse: CCT CTT GCC ACT TGC TTT
TC, Noxa Forward: AGT CGA GTG TGC TAC TCA ACT
A, Noxa Reverse: TGA TGT ATT CCA TCT TCC GTT T.
Statistical analysis
Statistical analysis of the data was carried out on GraphPad
InStat software using t tests, one-way ANOVA followed by
Student–Newman–Keuls post hoc test and two-way
ANOVA followed by Bonferroni post hoc test, where
appropriate. When the p value was \0.05, groups were
considered to be significantly different.
Results
TRAIL resistance in GBM cell lines can be attenuated
by decreasing expression levels of Mcl-1
In order to investigate TRAIL sensitivity and resistance in
GBM, a panel of three GBM cell lines, consisting of two
commercially available lines, A172 and U87 and a cell line
derived from a primary GBM tumour, MZ-294, were
treated with TRAIL for 24, 48 and 72 h (Fig 1a). All of
these cell lines have previously been shown to express the
TRAIL receptor DR5/TRAIL-R2 [22]. Following treat-
ment, U87 and MZ-294 cells were found to be resistant to
TRAIL-induced effects on cell viability. However, the
percentage of viable A172 cells was significantly decreased
following TRAIL treatment at all timepoints (Fig 1a).
Given that previous studies have linked Mcl-1 expression
levels and sensitivity to TRAIL treatment, we investigated
the basal levels of Mcl-1 expression in the cell lines and
observed that the TRAIL resistant cell lines, U87 and MZ-
294, expressed higher Mcl-1 protein levels in comparison
to the TRAIL sensitive cell line, A172 (Fig 1b). We
therefore next investigated the effect of suppression of
Mcl-1 expression using gene silencing technology on
TRAIL-induced apoptosis in the treatment-resistant MZ-
294 and U87 cells (Fig 1d, e). The cells were transfected
with a GFP vector expressing a Mcl-1 targeting shRNA
construct (Fig 1c; left panel) and the resultant reduction in
Mcl-1 expression was quantified using qPCR (Fig 1c; right
panel). The cells were subsequently treated with TRAIL for
48 h and counting transfected cells only, we observed that
the cells in which Mcl-1 expression was downregulated,
were significantly more sensitive to TRAIL-induced
apoptosis (Fig 1d, e).
632 Apoptosis (2014) 19:629–642
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Expression levels of Mcl-1 and Noxa in GBM cell lines
determine their resistance to R-roscovitine-induced
apoptosis
Since the attenuation of Mcl-1 expression partially re-
sensitized the resistant cell lines to TRAIL-induced apop-
tosis, we next examined the effect of treatment with
R-roscovitine, a known downregulator of Mcl-1, in our
panel of cell lines [32]. The cells were treated with
R-roscovitine for 24, 48 and 72 h. Treatment with R-ros-
covitine significantly decreased cell survival of the A172
and U87 cell lines compared with the MZ-294 cell line
(Fig 2a) and significantly increased the percentage of these
cells undergoing apoptosis compared with the MZ-294
cells (Fig 2b). Next we assessed the consequences of
R-roscovitine treatment on Mcl-1 expression and found
that Mcl-1 expression was downregulated at the protein
level in A172 cells as early as 24 h post treatment (Fig 2c)
and while R-roscovitine did decrease Mcl-1 expression in
U87 (Fig 2c), it did so to a lesser extent and at a later
timepoint than in A172 cells, corresponding to the lower
levels of cell death evident in this cell line (Fig 2b). The
sole targeting of Mcl-1 expression in A172 cells using
shRNA technology significantly increased the percentage
MZ-294 U87
Mcl-1
Actin
MZ-294 A172 U87
Hoechst GFP Composite
MZ-294
a
c
d e
b
Fig. 1 Mcl-1 downregulation enhances TRAIL-induced apoptosis in
MZ-294 and U87 GBM cell lines. a Commercially available GBM
cell lines A172 and U87, and a cell line derived from a primary
tumour, MZ-294, were treated with TRAIL (100 ng/ml) for 24, 48
and 72 h. After treatment, MTT assays were carried out to assess cell
viability. Data are expressed as mean ± SEM, **p \ 0.01;
***p \ 0.001 versus MZ-294 cells at the same timepoint, three
independent experiments. b Basal levels of Mcl-1 were assessed in
MZ-294, A172 and U87 cells by western blotting. Actin was used as a
loading control. c Images (scale bar = 20 lM) depicting transfection
efficiency of the GFP-expressing scramble control and Mcl-1
knockdown shRNA in MZ-294 cells and the subsequent knockdown
of Mcl-1 after 24 h are shown. d Following transfection with a GFP-
expressing Mcl-1 knockdown shRNA and treatment with TRAIL
(100 ng/ml) for 48 h, TRAIL-induced apoptosis of GFP? cells was
assessed by Hoechst staining in MZ-294 cells. e TRAIL-induced
apoptosis of GFP? cells was also assessed in U87 cells by Hoechst
staining. Data are expressed as mean ± SEM, **p \ 0.01;
***p \ 0.001 versus TRAIL only treated cells. Data are from three
independent experiments
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of cells undergoing apoptosis (Fig 2d) while downregula-
tion of Mcl-1 significantly potentiated the induction of cell
death with subsequent R-roscovitine treatment in both
A172 and U87 cells (Fig 2d).
We also observed that treatment of MZ-294 cells with
R-roscovitine decreased Mcl-1 levels in this cell line
(Fig 2c), without causing significant levels of cell death
(Fig 2b). As Noxa has been shown to be a critical effector
of apoptosis due to its ability to neutralize Mcl-1 [25, 33],
we next assessed the expression levels of Noxa during the
apoptotic death of the cells. Following R-roscovitine
treatment, we observed that expression of Noxa was
A172
MZ-294
Con 24h 48h 72h
R-roscovitine
Noxa
Actin
Noxa
Actin
17kDa
17kDa
42kDa
42kDa
A172
Con 24h 48h 72h Con 24h 48h 72h
R-roscovitine
42kDa
42kDa
U87
R-roscovitine
Mcl-1
Actin
R-roscovitine
Con 24h 48h 72h
MZ-294
A172 U87
a
c
d
e f
b
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targeted in both A172 and MZ-294 cells (Fig 2e). Inter-
estingly however, using BH3 profiling we observed that
A172 cells underwent greater levels of mitochondrial
depolarisation in response to the same concentration of
Noxa BH3 peptide when compared with MZ-294 cells
(Fig 2f) indicating that A172 cells are more sensitive to
apoptosis induction as a result of Mcl-1 inhibition than
MZ-294 cells.
R-roscovitine and TRAIL synergise to induce apoptosis
in MZ-294 cells
Having established a role for Mcl-1 in the resistance of our
GBM cell lines to chemotherapy-induced apoptosis, we
investigated if R-roscovitine, given its capacity to decrease
Mcl-1, and TRAIL could synergise to induce apoptosis in the
treatment-resistant MZ-294 cell line. The cells were treated
with either R-roscovitine or TRAIL or a combination of the
two for 48 h at concentrations previously used in the literature
[34]. There was a significant decrease in the viability of MZ-
294 cells (Fig 3a) following treatment with R-roscovi-
tine ? TRAIL compared with either treatment alone. This
was coupled with a significant increase in the percentage of
cells undergoing apoptosis as determined by propidium
iodide and Annexin V staining (Fig 3b, c, d) using flow
cytometry. A greater percentage of cells were Annexin
V-positive and PI-negative (36.9 %; Fig 3b) than were
Annexin V-negative and PI-positive (5.8 %; Fig 3c), indi-
cating that the majority of dying cells were undergoing
apoptosis [35]. Some cells labelled positive for both Annexin
V and PI (15.9 %; Fig 3d) indicating that some cells were also
undergoing necrosis, secondary to early apoptosis.
R-roscovitine ? TRAIL treatment induces apoptosis
in a 3D tumour model
Neurospheres were generated from MZ-294 cells to form a
3D tumour model. Such models more closely represent the
Fig. 3 R-roscovitine and
TRAIL synergise to induce
apoptosis in MZ-294 cells. MZ-
294 cells were treated with
R-roscovitine (20 lM), TRAIL
(100 ng/ml) and R-roscovitine
(20 lM) ? TRAIL (100 ng/ml)
for 48 h. a Cell viability
following treatment was
assessed by MTT assay. The
percentage of Annexin?PI- b,
Annexin-PI? c and
Annexin?PI? d cells following
treatment was determined using
flow cytometry. Data are
expressed as mean ± SEM,
**p \ 0.01; ***p \ 0.001
versus control; representative of
three independent experiments
Fig. 2 Knockdown of Mcl-1 augments R-roscovitine-induced
apoptosis in A172 and U87 GBM cell lines. The GBM cells lines
A172, U87 and MZ-294 were treated with R-roscovitine (20 lM) for
24, 48 and 72 h. a Cell viability was assessed using MTT assay and
b the induction of apoptosis was determined by Annexin staining
using flow cytometry. Data are expressed as mean ± SEM,
**p \ 0.01; ***p \ 0.001 versus MZ-294 cells at the same time-
point. Data are from three independent experiments. c Western blot
analysis of Mcl-1 expression was carried out on A172, U87 and MZ-
294 cells treated with R-roscovitine (20 lM) for 24, 48 and 72 h.
Actin was used as a loading control. d A172 and U87 cells were
transfected with GFP-expressing Mcl-1 knockdown shRNA and
subsequently treated with R-roscovitine (20 lM) for 48 h. The
percentage of apoptotic GFP? cells was determined by Hoechst
staining. Data are expressed as mean ± SEM, **p \ 0.01;
***p \ 0.001; data are from three independent experiments.
e A172 and MZ-294 cells were treated with R-roscovitine (20 lM)
for 24, 48 and 72 h and the expression of Noxa was determined by
western blot analysis. Actin was used as a loading control.
f Mitochondrial depolarisation, indicated by the ratiometric fluores-
cent dye JC1, was measured in A172 and MZ-294 cells treated with
Noxa BH3 peptide (100 lM). Depolarisation with Noxa BH3 peptide
was expressed as a percentage of depolarisation induced by the
protonophore, FCCP (100 %) compared to vehicle (DMSO),
*p \ 0.05; data are from three independent experiments
b
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cell–cell interactions and the limited O2 and nutrient
availability observed in a tumour in situ [36]. Thus we next
explored if the combined treatment strategy could also
target cells in our 3D GBM tumour model. Dissociated
neurospheres generated from MZ-294 cells were stained
for CD133 and nestin and were shown to preferentially
express these stem cell markers (Fig 4a) indicating that the
cells in the 3D tumour model display more undifferentiated
properties compared to the MZ-294 monolayer. The
neurospheres were allowed to form for 4 d and then treated
with R-roscovitine, TRAIL and R-roscovitine ? TRAIL
for 48 h. Images were taken of the neurospheres (Fig 4b)
and the diameters of the neurospheres were measured.
Treatment with R-roscovitine ? TRAIL significantly
decreased the diameters of the neurospheres and their
ability to proliferate and grow in size (Fig 4c). Treatment
Dapi CD133 Nestin Composite
MZ294 monolayer
MZ294 neurosphere cells
Rosc (20 µM) + 
TRAIL (100 ng/ml)
Control Rosc (20 µM)
TRAIL 
(100 ng/ml)
Procaspase
-3
Cleaved 
caspase-3 
Control
Rosc
(20 µM)
TRAIL
(100 ng/ml)
Rosc (20 µM) + 
TRAIL (100 ng/ml)
30kDa
17kDa
a b
c
d
e
f
Fig. 4 Treatment with R-roscovitine ? TRAIL induces apoptosis in
a 3D tumour model. MZ-294 neurospheres were generated from MZ-
294 monolayer cells cultured in serum-free neurosphere-forming
medium. a MZ-294 monolayer cells and MZ-294 neurospheres were
dissociated and cytospun onto slides and then stained with the stem
cell markers CD133, nestin and the nuclear marker Dapi (scale
bar = 20 lM). b MZ-294 neurospheres were treated with R-rosco-
vitine (20 lM), TRAIL (100 ng/ml), R-roscovitine (20 lM) ?
TRAIL (100 ng/ml) for 48 h. Brightfield images of the neurospheres
were taken post treatment (scale bar = 50 lM). c The diameters of
the neurospheres were measured following treatment with R-rosco-
vitine (20 lM), TRAIL (100 ng/ml), R-roscovitine (20 lM) ?
TRAIL (100 ng/ml) for 48 h using an Eclipse TE 300 inverted
microscope. Data are expressed as mean ± SEM, ***p \ 0.001;
n = 40–50 neurospheres. d Following treatment, neurospheres were
harvested for western blot analysis of the expression of pro-apoptotic
proteins procaspase-3 and cleaved caspase-3. e The percentage of
apoptotic neurosphere cells was determined by Annexin staining
using flow cytometry following treatment. Data are expressed as
mean ± SEM, ***p \ 0.001; data are from three independent
experiments. f The percentage of neurosphere cells expressing
CD133 and Nestin was assessed following treatment with R-rosco-
vitine (20 lM) ? TRAIL (100 ng/ml) for 48 h
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with R-roscovitine ? TRAIL also significantly increased
the expression of cleaved caspase-3 (Fig 4d), enhanced the
percentage of cells in the neurospheres undergoing apop-
tosis (Fig 4e) and decreased the percentage of cells that
were CD133 and nestin positive (Fig 4f).
R-roscovitine and TRAIL-induced apoptosis in MZ-294
cells is achieved through an Mcl-1/Noxa axis
As the combination therapy of TRAIL and R-roscovitine
was effective in inducing cell death in both the monolayer
and 3D neurospheres of a formerly treatment-resistant
GBM cell line, yet R-roscovitine was not capable of
altering the expression of the TRAIL receptors DR4 and
DR5 (Supplemental Fig 1), we focused our investigation
on the downstream cell death signalling pathways elicited
by this drug combination. We first determined the
expression of cFLIP in monolayer MZ-294 cells following
treatment and showed that R-roscovitine has the ability to
significantly downregulate the expression of cFLIP at 8 h
and 24 h when used alone and when used in combination
with TRAIL (Fig 5a; top and bottom panel). As cFLIP is a
known inhibitor of death receptor signalling [16], we next
assessed the ability of the differing treatment paradigms to
activate caspase-8 within the MZ-294 cells (Fig 5b). We
observed that treatment with TRAIL alone and in combi-
nation with R-roscovitine was sufficient to activate cas-
pase-8 as early as 8 h after treatment and this activation
persisted until 24 h (Fig 5b; top and bottom panel). How-
ever as significant levels of apoptotic cell death were only
evident using the combined treatment strategy (Fig 3), we
next focused on signalling events further downstream of
caspase-8 activation. Interestingly, while we found no
evidence of significant changes in the expression levels of
Bid under any of the treatment strategies at the indicated
time-points (Fig 5c; top and bottom panel), we did detect
activation of caspase-3 as early as 8 h following treatment
(Fig 5e; top and bottom panel) and similar to caspase-8,
caspase-3 activation persisted until 24 h in both the TRAIL
treated and TRAIL and R-roscovitine treated cells (Fig 5e;
top and bottom panel). However, as TRAIL treatment
alone did not kill the cells (Fig 1) despite such caspase-3
activation, we next examined the levels of Mcl-1 expres-
sion, a known target of R-roscovitine (Fig 5d; top and
bottom panel). The observed downregulation of Mcl-1
coincided with caspase-8 and caspase-3 activation in the
TRAIL and R-roscovitine treated cells while being absent
from the TRAIL alone treated cells, indicating that the
downregulation of Mcl-1 was a significant event in the cell
death observed in the dual treatment strategy. To further
investigate the potential contribution of Mcl-1 in our
combined treatment paradigm, we examined the expression
levels of both Mcl-1 and its pro-apoptotic binding partner
Noxa, in MZ-294 monolayer cells following treatment with
R-roscovitine, TRAIL and combined R-roscovitine and
TRAIL (Fig 6a). In the R-roscovitine-only treated cells,
and the dual therapy treated cells we saw downregulation
of Mcl-1 protein levels, coupled with a decrease in Noxa
expression levels. In the cells treated with TRAIL mono-
therapy, which did not evoke any cell death (Fig 1a), the
expression of both Mcl-1 and Noxa remained similar to
control levels. Following transfection with GFP vector
expressing a Noxa-targeting shRNA (Fig 6b; top panel),
we show significant knockdown of Noxa at the mRNA
level (Fig 6b). Counting transfected cells only, pertinently,
we saw that knockdown of Noxa significantly attenuated
the levels of apoptosis observed following treatment of
MZ-294 cells with R-roscovitine alone and R-roscovi-
tine ? TRAIL (Fig 6c), demonstrating that Noxa must be
present for R-roscovitine and R-roscovitine ? TRAIL-
induced apoptosis of GBM to proceed.
Discussion
The significant findings of this study demonstrate that the
expression of Mcl-1 in GBM cells plays a critical role in
determining their sensitivity to TRAIL-induced apoptosis
and that the effective targeting of Mcl-1 in TRAIL resistant
GBM cells can establish sensitivity to TRAIL, both within
the bulk cell population and crucially within the 3D tumour
model. We also highlight that two separate pathways are
activated during the apoptotic death of GBM cells treated
with the combined chemotherapeutic agents, TRAIL and the
Mcl-1-targeting, cyclin-dependent kinase inhibitor, R-ros-
covitine, one which leads to caspase-8 and caspase-3 acti-
vation and a second pathway, involving a Mcl-1:Noxa axis.
The pivotal role Mcl-1 plays in protecting cancer cells
from apoptosis is well documented [37]. In GBM cells in
particular, the downregulation of Mcl-1 using miRNA has
been shown to significantly decrease cell proliferation and
increase apoptosis [38]. Additionally, targeting of Mcl-1
using shRNA has been demonstrated to sensitize glioma
stem cells to the small molecule inhibitor, ABT-737 [39].
In this study we have found that the downregulation of
Mcl-1 is also an effective method to establish TRAIL-
induced apoptosis in TRAIL resistant GBM cells. To our
knowledge this is the first time that Mcl-1 levels and
TRAIL sensitivity have been shown to be inversely cor-
related in GBM. Our observations emphasize the necessity
to investigate Mcl-1 expression levels prior to the thera-
peutic utilization of TRAIL in GBM patients, especially
when one considers the high levels of Mcl-1 expression
reported in tumours isolated from such patients [4].
TRAIL has displayed excellent potential as a novel
therapeutic agent in the treatment of GBM [19]. It is now
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well documented that while some glioma cell lines are
sensitive to the apoptotic effects of TRAIL, the majority of
glioma cell lines and patient samples are resistant [19, 22,
40]; therefore, combinatorial approaches with conventional
chemotherapies or novel targeted therapies may be required
to ensure the therapeutic potential of TRAIL in GBM
treatment is fully exploited [19]. Accordingly cisplatin [41],
the pharmacological targeting of Bcl-2 and Bcl-x [22],
proteasome inhibitors [40, 42, 43] and histone deacetylase
inhibitors [44] have all been proven to be effective at
establishing TRAIL sensitivity within GBM. In this study,
we demonstrated that strategies aimed at downregulating
Mcl-1 expression, such as shRNA or the cyclin-dependent
kinase inhibitor, R-roscovitine, have the potential to estab-
lish TRAIL-induced killing in GBM. R-roscovitine down-
regulates Mcl-1 expression through its ability to induce
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Fig. 5 Altered expression of apoptosis-associated proteins in MZ-
294 cells following treatment with R-roscovitine ? TRAIL. MZ-294
cells were treated with R-roscovitine (20 lM), TRAIL (100 ng/ml),
R-roscovitine (20 lM) ? TRAIL (100 ng/ml) for 8 and 24 h. Top
panel: Sample western blot images of the expression of the apoptosis-
associated proteins a cFLIP, b procaspase-8 c Bid, d the anti-
apoptotic protein Mcl-1 and e pro and cleaved caspase-3 following
treatment. Actin was used as a loading control. Bottom panel: Graphs
depicting densitometry analysis of the indicated protein levels at 8 h
and 24 h following treatment. Data are from three independent
experiments. *p \ 0.05, **p \ 0.01, ***p \ 0.001 versus control
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rapid dephosphorylation of RNA polymerase II [45]. Given
that R-roscovitine can cross the blood brain barrier [46], this
approach to silencing Mcl-1 expression levels may be more
clinically feasible than using shRNA technology to enhance
TRAIL-induced apoptotic effects in vivo. R-roscovitine-
induced inhibitory effects on cyclin-dependent kinases and
attenuating effects on Mcl-1 expression levels have been
associated with the induction of secondary necrosis in
immune cells [47, 48]. While not a direct focus of our study,
secondary necrosis may also contribute to the cell death
observed. However, the majority of cells were Annexin
V-positive and PI-negative suggesting that the preferred
pathway in our model system is apoptosis. Our observation
that combined R-roscovitine and TRAIL treatment also
successfully induced apoptosis in the 3D tumour model,
which more accurately represents the tumour environment
in vivo, further enhances the potential of this combination as
a relevant therapeutic in the treatment of GBM.
In this study, we demonstrate that R-roscovitine-induced
sensitisation of MZ-294 cells to TRAIL is not dependent
on upregulation of the TRAIL death receptors, DR4 and
DR5. The inability of R-roscovitine to alter the expression
of DR4 and DR5 was previously reported in a study by
Kim et al. [34] and thus our investigations focused on the
downstream signalling pathways elicited by the combina-
tion therapy of R-roscovitine and TRAIL in our TRAIL
resistant GBM cells. We observed the potential contribu-
tion from two parallel cell death pathways.
We initially demonstrated that R-roscovitine decreased
the expression of the protein, cFLIP, in MZ-294 cells when
used alone or in combination with TRAIL. Subsequently,
we saw evidence of caspase-8 activation in both the TRAIL
alone and combined treatment paradigms, indicating that
R-roscovitine-mediated cFLIP downregulation alone was
insufficient to trigger caspase-8 activation and that a
TRAIL signalling pathway was critical to facilitate
Hoechst GFP Composite
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Actin
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Fig. 6 The Mcl-1/Noxa axis plays a critical role in R-roscovitine and
TRAIL-induced apoptosis in MZ-294 monolayer cells. a MZ-294
cells were treated with R-roscovitine (20 lM), TRAIL (100 ng/ml)
and R-roscovitine (20 lM) ? TRAIL (100 ng/ml) for 24 h and the
expression of Mcl-1 and Noxa was assessed by western blot analysis.
Actin was used as a loading control. b Images (scale bar = 20 lM)
depicting transfection efficiency of the GFP-expressing scramble
control and Noxa knockdown shRNA in MZ-294 cells and the
subsequent knockdown of Noxa after 72 h are shown. c MZ-294 cells
were transfected with a GFP-expressing Noxa knockdown shRNA
and treated with R-roscovitine (20 lM) or R-roscovitine
(20 lM) ? TRAIL (100 ng/ml) for 48 h. The percentage of apoptotic
GFP? cells was determined by Hoechst staining. Data is expressed as
mean ± SEM, **p \ 0.01; ***p \ 0.001 versus control cells;
?p\0.05 versus R-roscovitine treated cells; ???p \ 0.001 versus
R-roscovitine ? TRAIL treated cells; data are from three indepen-
dent experiments
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caspase-8 activation. Greater levels of caspase-8 activation
were achieved using the dual treatments as TRAIL sig-
nalling occurred concomitantly with cFLIP downregula-
tion. Previous studies in multiple cancer types, using
various methods to downregulate cFLIP expression, have
demonstrated similar effects on the enhancement of TRAIL
signalling, for e.g., cycloheximide in renal cancer cells
[49], histone deacetylase inhibitors in glioma cells [44] and
R-roscovitine in breast cancer cells [50]. As Bid is usually
described as the main link between the extrinsic and the
intrinsic apoptotic pathways in type II cells [51], we next
examined the conversion of Bid to tBid and interestingly
only observed the appearance of tBid at approximately
72 h post treatment (data not shown). Coinciding with
procaspase-8 activation, however, was the activation of
procaspase-3 in the TRAIL alone and combined treatment
regimens. In the absence of tBid, such cleavage and acti-
vation of procaspase-3 may be the result of direct pro-
cessing by active caspase-8 [52]. Similar to caspase-8
activation, greater levels of active caspase-3 were achieved
using the dual treatment strategy. We detected cleaved
caspase-3 in the TRAIL alone treated cells, which did not
die. Such sub-lethal caspase-3 signalling has previously
been reported by Aldridge and colleagues in their models
of TRAIL-induced apoptosis [53]. It is interesting to
speculate that this sub-lethal level of caspase-3 activation
could perhaps be promoting growth rather than death, a
role that has previously been suggested for caspase-3 in
tumour cells [54]. This is the first time such caspase-3-type
activity has been reported for glioblastoma cells and war-
rants further investigation.
Concurrently, we investigated the role of Mcl-1, a
known target of R-roscovitine, in our treatment paradigm.
Initially, we observed Mcl-1 downregulation following
R-roscovitine treatment; however, this was insufficient to
induce a significant level of apoptosis due in part to the
lack of caspase-3 activation in these cells. Treatment of the
cells with TRAIL alone had little effect on Mcl-1 expres-
sion levels, emphasising the requirement for Mcl-1 down-
regulation in the execution of apoptosis, even in the
presence of caspase-3 activation. Following the combined
treatment of both R-roscovitine and TRAIL, we observed
targeting of Mcl-1, activation of caspase-3 and pertinently,
significant levels of cell death were achieved.
Examination of the expression levels of Mcl-1 and Noxa
in all of the treatment strategies suggested to us that the
interplay between Mcl-1 and Noxa levels played a role in
attaining the observed levels of cell death. Previous reports
have highlighted the ratio between these two proteins is
essential in the sensitization of melanoma cells to ABT-737
[55] and in the sensitization of glioma cells by bortezomib
to vorinostat-induced apoptosis [56]. Zhang et al.’s findings
add further weight to our hypothesis as their study in HeLa
cells highlights that Noxa functions as a constitutive
inhibitor of Mcl-1, which remains associated with Mcl-1
even during TRAIL treatment. Upon knockdown of Noxa
however, there is a significant decrease in the levels of
TRAIL-induced apoptosis as such knockdown results in an
effective increase in the levels of free/active Mcl-1 [25]. To
verify a role for Noxa in our R-roscovitine ? TRAIL
treatment strategy, we silenced Noxa protein expression by
shRNA targeting and highlighted that this restored resis-
tance to the combined treatment regime in the MZ-294
cells. Such findings are particularly pertinent in light of
studies which demonstrate that overexpression of the anti-
apoptotic proteins, Bcl-2 or Bcl-xL, neither of which are
capable of binding Noxa, had no effect on subsequent
combined R-roscovitine and TRAIL treatment in glioma
cells [34].
The exact series of events in the final execution of
apoptosis by these two parallel death pathways has yet to
be fully elucidated. It is interesting to hypothesise that as a
result of Mcl-1 downregulation following R-roscovitine
and TRAIL treatment, Noxa is capable of displacing the
activator BH3-only protein, Bim, and the pro-apoptotic
protein, Bak, from Mcl-1:Bim and Mcl-1:Bak complexes
respectively [55, 57], thereby triggering mitochondrial
dysfunction, caspase activation and ultimately apoptosis
[55, 57]. Feeding into this pathway is the direct activation
of caspases-8 and -3, which alone do not appear to be
sufficient to trigger significant levels of cell death. These
active caspases may also contribute to the observed
downregulation of Mcl-1 expression following R-roscovi-
tine and TRAIL treatment since both have been shown to
mediate cleavage of Mcl-1 and loss of Mcl-1 expression
[58], thereby freeing further Bim or Bak. Our observation
that the silencing of Noxa protein expression also resulted
in resistance to the limited levels of cell death induced by
R-roscovitine treatment alone adds further weight to our
argument that TRAIL-mediated activation of caspases-8
and -3 makes an important contribution to the significant
levels of cell death we observed using the dual treatment
strategy.
Taken together, this study provides convincing evidence
that a combinational therapeutic treatment regime that
modulates Mcl-1 expression levels may be an efficacious
approach to sensitize GBM to the apoptosis-inducing
effects of TRAIL. Undoubtedly, R-roscovitine in combi-
nation with TRAIL presents a promising novel strategy to
trigger cell death pathways in glioblastoma and warrants
further investigation.
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